13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q4 2025 · Filed February 17, 2026 · Accession 0001012975-26-000153
Total Value
$651.7M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MAZE THERAPEUTICS INC. | MAZE | 4,120,053 | $170.7M | 26.19% |
| 2 | BEAM THERAPEUTICS INC. | BEAM | 4,540,132 | $125.9M | 19.31% |
| 3 | RAPPORT THERAPEUTICS INC. | RAPP | 3,728,738 | $113.1M | 17.36% |
| 4 | LYELL IMMUNOPHARMA INC. | LYEL | 2,759,072 | $84.9M | 13.03% |
| 5 | VIR BIOTECHNOLOGY INC. | VIR | 12,916,663 | $77.9M | 11.95% |
| 6 | ERASCA INC. | ERAS | 11,055,554 | $41.1M | 6.31% |
| 7 | GOSSAMER BIO INC. | GOSS | 8,055,916 | $25.0M | 3.83% |
| 8 | 10X GENOMICS INC. | TXG | 737,539 | $12.0M | 1.85% |
| 9 | Q32 BIO INC. | QTTB | 320,482 | $1.1M | 0.16% |